Secondary Logo

Institutional members access full text with Ovid®

Nutraceuticals - a pharmaceutical viewpoint: part II

Hardy, Gila; Hardy, Inesa; Ball, Patrick Ab

Current Opinion in Clinical Nutrition and Metabolic Care: November 2003 - Volume 6 - Issue 6 - p 661-671
Micronutrients, neutraceutics and functional foods

Purpose of review To review pharmaceutical and pharmacological issues relating to the benefits and risks associated with the use of naturally sourced nutraceuticals when administered singly or in combinations.

Recent findings The application of vegetable extracts or dietary supplementation with selenium or antioxidant vitamins results in positive benefits on immunity and other phenomena associated with chronic diseases, ageing and cancer. However, there appear to be no cardiovascular benefits from vitamin mixtures, which may in fact cause harm. Therefore, although recent publications have increased our understanding of the metabolic actions of nutraceuticals, learning to use them to the best advantage is going to require products with uniform and consistent quality. Unfortunately, a single purified substance will not always have the same antioxidant activity, nor provide the same clinical benefits as nutraceutical mixtures and combinations occurring in natural extracts. In order to perform first-class clinical studies to determine safety and efficacy, the stability, compatibility and other pharmaceutical variables inherent in many of these combination products will have to be better controlled.

Summary Nutraceuticals have potent biological actions. Their use is increasing dramatically, and there is growing evidence of clinical benefits. No medicinal products are completely safe so their risks need to be characterized and controlled. Imposing pharmaceutical levels of control and regulation would increase costs and reduce patient access to new products, but the evidence is compelling that closer monitoring of raw materials, processing and formulation will be required to maximize the benefits and minimize the risks.

aPharmaceutical Nutrition Research Group, Witney, Oxford, UK; and bSchool of Pharmacy, University of Auckland, Auckland, New Zealand

Correspondence to Professor Gil Hardy, Pharmaceutical Nutrition Research Group, PO Box 110, Witney, Oxford OX29 7FJ, UK Tel: +44 (0)1993 709 752; fax: +44 (0)1993 709 754; e-mail:

© 2003 Lippincott Williams & Wilkins, Inc.